10X Genomics Receives $35 million in Series D Financing

Recently, 10X Genomics announced a new round of funding during JPM. The fiancing of D round raised 35 million dollars,led by Meritech Capital and backed by Fidelity, Wells Fargo, Paladin Capital and softbank.

10X Genomics is a leader in the gene sequencing industry, providing accurate and complete gene sequencing services to research institutions around the world. Founded in 2012, 10X Genomics is a high-profile black horse in the field of gene sequencing. It has been well received by capital and has accumulated a total of 243 million dollars in just a few years.

In the past six months, 10X Genomics has made two significant acquisitions: Epinomics, an epigenetics-focused company, and Spatial Transcriptomics, a developer of two-dimensional gene expression technology. These two acquisitions have further cemented 10X Genomics as the leader in the gene-sequencing industry.

From 2015 to 2017, 10X Genomics' revenue increased 20 times, which also reflects the strong demand for its genetic sequencing products.

Dr. Serge Saxonov, CEO of 10X Genomics, said: “In the past year, 10X Genomics has grown and expanded, released new products, and welcomed the joining of two outstanding companies. We hope to maintain growth rates on the existing foundation. It will be a tenfold increase on its current size and become a company that affects the lives of billions of people around the world.”